394 results on '"Yashar, Catheryn M."'
Search Results
2. Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics
- Author
-
Yusufaly, Tahir I, Zou, Jingjing, Nelson, Tyler J, Williamson, Casey W, Simon, Aaron, Singhal, Meenakshi, Liu, Hannah, Wong, Hank, Saenz, Cheryl C, Mayadev, Jyoti, McHale, Michael T, Yashar, Catheryn M, Eskander, Ramez, Sharabi, Andrew, Hoh, Carl K, Obrzut, Sebastian, and Mell, Loren K
- Subjects
Biomedical Imaging ,Bioengineering ,Cancer ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Good Health and Well Being ,Female ,Fluorodeoxyglucose F18 ,Humans ,Neoplasm Recurrence ,Local ,Positron Emission Tomography Computed Tomography ,Prognosis ,Retrospective Studies ,Treatment Failure ,Uterine Cervical Neoplasms ,oncology: GYN ,PET/CT ,statistical ,analysis ,cervical cancer ,outcomes ,radiomics ,whole-body ,Clinical Sciences ,Nuclear Medicine & Medical Imaging - Abstract
Radiomics has been applied to predict recurrence in several disease sites, but current approaches are typically restricted to analyzing tumor features, neglecting nontumor information in the rest of the body. The purpose of this work was to develop and validate a model incorporating nontumor radiomics, including whole-body features, to predict treatment outcomes in patients with previously untreated locoregionally advanced cervical cancer. Methods: We analyzed 127 cervical cancer patients treated definitively with chemoradiotherapy and intracavitary brachytherapy. All patients underwent pretreatment whole-body 18F-FDG PET/CT. To quantify effects due to the tumor itself, the gross tumor volume (GTV) was directly contoured on the PET/CT image. Meanwhile, to quantify effects arising from the rest of the body, the planning target volume (PTV) was deformably registered from each planning CT to the PET/CT scan, and a semiautomated approach combining seed-growing and manual contour review generated whole-body muscle, bone, and fat segmentations on each PET/CT image. A total of 965 radiomic features were extracted for GTV, PTV, muscle, bone, and fat. Ninety-five patients were used to train a Cox model of disease recurrence including both radiomic and clinical features (age, stage, tumor grade, histology, and baseline complete blood cell counts), using bagging and split-sample-validation for feature reduction and model selection. To further avoid overfitting, the resulting models were tested for generalization on the remaining 32 patients, by calculating a risk score based on Cox regression and evaluating the c-index (c-index > 0.5 indicates predictive power). Results: Optimal performance was seen in a Cox model including 1 clinical biomarker (whether or not a tumor was stage III-IVA), 2 GTV radiomic biomarkers (PET gray-level size-zone matrix small area low gray level emphasis and zone entropy), 1 PTV radiomic biomarker (major axis length), and 1 whole-body radiomic biomarker (CT bone root mean square). In particular, stratification into high- and low-risk groups, based on the linear risk score from this Cox model, resulted in a hazard ratio of 0.019 (95% CI, 0.004, 0.082), an improvement over stratification based on clinical stage alone, which had a hazard ratio of 0.36 (95% CI, 0.16, 0.83). Conclusion: Incorporating nontumor radiomic biomarkers can improve the performance of prognostic models compared with using only clinical and tumor radiomic biomarkers. Future work should look to further test these models in larger, multiinstitutional cohorts.
- Published
- 2022
3. Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial
- Author
-
Williamson, Casey W, Sirák, Igor, Xu, Ronghui, Portelance, Lorraine, Wei, Lichun, Tarnawski, Rafal, Mahantshetty, Umesh, Heide, Elena S, Yashar, Catheryn M, McHale, Michael T, Bosch, Walter, Lowenstein, Jessica, Saenz, Cheryl C, Plaxe, Steve, Eskander, Ramez, Einck, John, Mundt, Arno J, Mayadev, Jyoti, and Mell, Loren K
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Trials and Supportive Activities ,Clinical Research ,Comparative Effectiveness Research ,Bone Marrow ,Cisplatin ,Female ,Humans ,Positron-Emission Tomography ,Radiotherapy ,Image-Guided ,Radiotherapy ,Intensity-Modulated ,Treatment Outcome ,Uterine Cervical Neoplasms ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeTo test effects of positron emission tomography (PET)-based bone marrow-sparing (BMS) image-guided intensity modulated radiation therapy (IG-IMRT) on efficacy and toxicity for patients with locoregionally advanced cervical cancer.Methods and materialsIn an international phase II/III trial, patients with stage IB-IVA cervical carcinoma were treated with either PET-based BMS-IG-IMRT (PET-BMS-IMRT group) or standard image-guided IMRT (IMRT group), with concurrent cisplatin (40 mg/m2 weekly), followed by brachytherapy. The phase II component nonrandomly assigned patients to PET-BMS-IMRT or standard IMRT. The phase III trial randomized patients to PET-BMS-IMRT versus IMRT, with a primary endpoint of progression-free survival (PFS) but was closed early for futility. Phase III patients were analyzed separately and in combination with phase II patients, comparing acute hematologic toxicity, cisplatin delivery, PFS, overall survival (OS), and patterns of failure. In a post-hoc exploratory analysis, we investigated the association between pretreatment absolute lymphocyte count (ALC) and OS.ResultsIn total, 101 patients were enrolled on the phase II/III trial, including 29 enrolled in phase III (PET-BMS-IMRT group: 16; IMRT group: 13) before early closure. Median follow-up was 33 months for phase III patients and 39 months for all patients. PFS and OS at 5 years for all patients were 73.6% (95% confidence interval [CI], 64.9%-84.3%) and 84% (95% CI, 76%-92.9%]), respectively. There were no differences in number of cisplatin cycles, OS, PFS, or patterns of failure between groups for the combined cohort. The incidence of acute grade ≥ 3 neutropenia was significantly lower in the PET-BMS-IMRT group compared with IMRT for randomized patients (19% vs 54%, χ2P = .048) and in the combined cohort (13% vs 35%, χ2P = .01). Patients with pretreatment ALC ≤ 1.5 k/µL had nonsignificantly worse OS on multivariable analysis (HR 2.85; 95% CI, 0.94-8.62; adjusted P = .216), compared with patients with ALC > 1.5 k/µL. There was no difference in posttreatment ALC by treatment group.ConclusionsPET-BMS-IMRT significantly reduced acute grade ≥3 neutropenia, but not treatment-related lymphopenia, compared with standard IMRT. We found no evidence that PET-BMS-IMRT affected chemotherapy delivery or long-term outcomes, and weak evidence of an association between pretreatment ALC and OS.
- Published
- 2022
4. What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Author
-
de Boer, Stephanie M., primary and Yashar, Catheryn M., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Gynecological Cancer
- Author
-
Mayr, Nina A., Lee, Larissa J., Small, William, Jr, Yashar, Catheryn M., Grosu, Anca-Ligia, editor, Nieder, Carsten, editor, and Nicolay, Nils Henrik, editor
- Published
- 2023
- Full Text
- View/download PDF
6. Knowledge-based dose prediction models to inform gynecologic brachytherapy needle supplementation for locally advanced cervical cancer
- Author
-
Kallis, Karoline, Mayadev, Jyoti, Kisling, Kelly, Brown, Derek, Scanderbeg, Daniel, Ray, Xenia, Cortes, Katherina, Simon, Aaron, Yashar, Catheryn M, Einck, John P, Mell, Loren K, Moore, Kevin L, and Meyers, Sandra M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Brachytherapy ,Dietary Supplements ,Female ,Humans ,Needles ,Radiotherapy Dosage ,Uterine Cervical Neoplasms ,knowledge-based ,Dose prediction ,Cervix cancer ,Needle supplementation ,Clinical Sciences ,Oncology & Carcinogenesis ,Clinical sciences - Abstract
PurposeThe use of interstitial needles, combined with intracavitary applicators, enables customized dose distributions and is beneficial for complex cases, but increases procedure time. Overall, applicator selection is not standardized and depends on physician expertise and preference. The purpose of this study is to determine whether dose prediction models can guide needle supplementation decision-making for cervical cancer.Materials and methodsIntracavitary knowledge-based models for organ-at-risk (OAR) dose estimation were trained and validated for tandem-and-ring/ovoids (T&R/T&O) implants. Models were applied to hybrid cases with 1-3 implanted needles to predict OAR dose without needles. As a reference, 70/67 hybrid T&R/T&O cases were replanned without needles, following a standardized procedure guided by dose predictions. If a replanned dose exceeded the dose objective, the case was categorized as requiring needles. Receiver operating characteristic (ROC) curves of needle classification accuracy were generated. Optimal classification thresholds were determined from the Youden Index.ResultsNeedle supplementation reduced dose to OARs. However, 67%/39% of replans for T&R/T&O met all dose constraints without needles. The ROC for T&R/T&O models had an area-under-curve of 0.89/0.86, proving high classification accuracy. The optimal threshold of 99%/101% of the dose limit for T&R/T&O resulted in classification sensitivity and specificity of 78%/86% and 85%/78%.ConclusionsNeedle supplementation reduced OAR dose for most cases but was not always required to meet standard dose objectives, particularly for T&R cases. Our knowledge-based dose prediction model accurately identified cases that could have met constraints without needle supplementation, suggesting that such models may be beneficial for applicator selection.
- Published
- 2021
7. Evaluation of dose differences between intracavitary applicators for cervical brachytherapy using knowledge-based models
- Author
-
Kallis, Karoline, Mayadev, Jyoti, Covele, Brent, Brown, Derek, Scanderbeg, Daniel, Simon, Aaron, Frisbie-Firsching, Helena, Yashar, Catheryn M, Einck, John P, Mell, Loren K, Moore, Kevin L, and Meyers, Sandra M
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Cervical Cancer ,Clinical Research ,Urologic Diseases ,Good Health and Well Being ,Brachytherapy ,Female ,Humans ,Organs at Risk ,Radiotherapy Dosage ,Radiotherapy Planning ,Computer-Assisted ,Rectum ,Uterine Cervical Neoplasms ,Knowledge-based planning ,Dose prediction ,Cervical cancer ,Intracavitary brachytherapy ,Tandem and ovoids ,Tandem and ring ,Clinical Sciences ,Oncology & Carcinogenesis ,Clinical sciences - Abstract
PurposeCurrently, there is a lack of patient-specific tools to guide brachytherapy planning and applicator choice for cervical cancer. The purpose of this study is to evaluate the accuracy of organ-at-risk (OAR) dose predictions using knowledge-based intracavitary models, and the use of these models and clinical data to determine the dosimetric differences of tandem-and-ring (T&R) and tandem-and-ovoids (T&O) applicators.Materials and methodsKnowledge-based models, which predict organ D2cc, were trained on 77/75 cases and validated on 32/38 for T&R/T&O applicators. Model performance was quantified using ΔD2cc=D2cc,actual-D2cc,predicted, with standard deviation (σ(ΔD2cc)) representing precision. Model-predicted applicator dose differences were determined by applying T&O models to T&R cases, and vice versa, and compared to clinically-achieved D2cc differences. Applicator differences were assessed using a Student's t-test (p < 0.05 significant).ResultsValidation T&O/T&R model precision was 0.65/0.55 Gy, 0.55/0.38 Gy, and 0.43/0.60 Gy for bladder, rectum and sigmoid, respectively, and similar to training. When applying T&O/T&R models to T&R/T&O cases, bladder, rectum and sigmoid D2cc values in EQD2 were on average 5.69/2.62 Gy, 7.31/6.15 Gy and 3.65/0.69 Gy lower for T&R, with similar HRCTV volume and coverage. Clinical data also showed lower T&R OAR doses, with mean EQD2 D2cc deviations of 0.61 Gy, 7.96 Gy (p < 0.01) and 5.86 Gy (p < 0.01) for bladder, rectum and sigmoid.ConclusionsAccurate knowledge-based dose prediction models were developed for two common intracavitary applicators. These models could be beneficial for standardizing and improving the quality of brachytherapy plans. Both models and clinical data suggest that significant OAR sparing can be achieved with T&R over T&O applicators, particularly for the rectum.
- Published
- 2021
8. Recent Trends in Medicare Payments for Outpatient Cancer Care at the End of Life
- Author
-
Mantz, Constantine A., Yashar, Catheryn M., Bajaj, Gopal K., and Sandler, Howard M.
- Published
- 2023
- Full Text
- View/download PDF
9. Contributors
- Author
-
Backes, Floor J., primary, Beffa, Lindsey B., additional, Billingsley, Caroline C., additional, Birrer, Michael J., additional, Bixel, Kristin, additional, Boitano, Teresa K.L., additional, Brewster, Wendy R., additional, Chase, Dana M., additional, Bruce, Shaina, additional, Crown, Angelena, additional, Chu, Christina S., additional, Clarke-Pearson, Daniel L., additional, Ross, Robert A., additional, Crosland, Brian, additional, Cohen, Joshua G., additional, Coleman, Robert L., additional, DiSilvestro, Paul A., additional, Dorigo, Oliver, additional, Duska, Linda R., additional, Eskander, Ramez Nassef, additional, Gemignani, Mary L., additional, Gunderson, Camille Catherine, additional, Hagemann, Andrea R., additional, Herzog, Thomas J., additional, Korenaga, Travis R., additional, Huh, Warner K., additional, Kuroki, Lindsay, additional, Kurnit, Katherine, additional, Mannel, Robert S., additional, Massad, L. Stewart, additional, Mathews, Cara A., additional, Miller, David S., additional, Monk, Bradley J., additional, Mutch, David G., additional, Nikam, Rachita, additional, Pinkerton, JoAnn V., additional, Powell, Matthew, additional, Rash, Dominique L., additional, Landrum, Lisa M., additional, Ring, Kari L., additional, Renz, Malte, additional, Roane, Brandon, additional, Rubin, Stephen C., additional, Salani, Ritu, additional, Satero, Jane, additional, Sood, Anil K., additional, Soper, John T., additional, Stock, Elizabeth Christina, additional, Sung, C. James, additional, Tewari, Krishnansu Sujata, additional, Toboni, Michael D., additional, Tucker, Katherine, additional, Walker, Joan L., additional, Wall, Jaclyn A., additional, Washington, Christina, additional, Wenzel, Lari B., additional, Westin, Shannon N., additional, Yashar, Catheryn M., additional, Creasman, William T., additional, and Zuna, Rosemary E., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Basic principles in gynecologic radiotherapy
- Author
-
Rash, Dominique Lan, primary and Yashar, Catheryn M., additional
- Published
- 2023
- Full Text
- View/download PDF
11. A knowledge-based organ dose prediction tool for brachytherapy treatment planning of patients with cervical cancer
- Author
-
Yusufaly, Tahir I, Kallis, Karoline, Simon, Aaron, Mayadev, Jyoti, Yashar, Catheryn M, Einck, John P, Mell, Loren K, Brown, Derek, Scanderbeg, Daniel, Hild, Sebastian J, Covele, Brent, Moore, Kevin L, and Meyers, Sandra M
- Subjects
Clinical Research ,Urologic Diseases ,Cancer ,Adult ,Brachytherapy ,Colon ,Sigmoid ,Female ,Humans ,Organs at Risk ,Radiotherapy Dosage ,Radiotherapy Planning ,Computer-Assisted ,Rectum ,Tomography ,X-Ray Computed ,Urinary Bladder ,Uterine Cervical Neoplasms ,Knowledge-based planning ,Cervical cancer ,Dose predictions ,Machine learning ,Quality control ,Treatment planning ,Clinical Sciences ,Oncology & Carcinogenesis - Abstract
PurposeThe purpose of this study is to explore knowledge-based organ-at-risk dose estimation for intracavitary brachytherapy planning for cervical cancer. Using established external-beam knowledge-based dose-volume histogram (DVH) estimation methods, we sought to predict bladder, rectum, and sigmoid D2cc for tandem and ovoid treatments.Methods and materialsA total of 136 patients with loco-regionally advanced cervical cancer treated with 456 (356:100 training:validation ratio) CT-based tandem and ovoid brachytherapy fractions were analyzed. Single fraction prescription doses were 5.5-8 Gy with dose criteria for the high-risk clinical target volume, bladder, rectum, and sigmoid. DVH estimations were obtained by subdividing training set organs-at-risk into high-risk clinical target volume boundary distance subvolumes and computing cohort-averaged differential DVHs. Full DVH estimation was then performed on the training and validation sets. Model performance was quantified by ΔD2cc = D2cc(actual)-D2cc(predicted) (mean and standard deviation). ΔD2cc between training and validation sets were compared with a Student's t test (p < 0.01 significant). Categorical variables (physician, fraction-number, total fractions, and case complexity) that might explain model variance were examined using an analysis of variance test (Bonferroni-corrected p < 0.01 threshold).ResultsTraining set deviations were bladder ΔD2cc = -0.04 ± 0.61 Gy, rectum ΔD2cc = 0.02 ± 0.57 Gy, and sigmoid ΔD2cc = -0.05 ± 0.52 Gy. Model predictions on validation set did not statistically differ: bladder ΔD2cc = -0.02 ± 0.46 Gy (p = 0.80), rectum ΔD2cc = -0.007 ± 0.47 Gy (p = 0.53), and sigmoid ΔD2cc = -0.07 ± 0.47 Gy (p = 0.70). The only significant categorical variable was the attending physician for bladder and rectum ΔD2cc. CONCLUSION: A simple boundary distance-driven knowledge-based DVH estimation exhibited promising results in predicting critical brachytherapy dose metrics. Future work will examine the utility of these predictions for quality control and automated brachytherapy planning.
- Published
- 2020
12. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma
- Author
-
Mell, Loren K, Xu, Ronghui, Yashar, Catheryn M, McHale, Michael T, Einck, John P, Mayadev, Jyoti, Lee, Euyhyun, Binder, Pratibha, Rash, Dominique, Eskander, Ramez, Heide, Elena S, Plaxe, Steven C, Mundt, Arno J, and Saenz, Cheryl C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Cervical Cancer ,Clinical Trials and Supportive Activities ,Digestive Diseases ,Cancer ,6.5 Radiotherapy and other non-invasive therapies ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Cisplatin ,Combined Modality Therapy ,Deoxycytidine ,Female ,Humans ,Middle Aged ,Radiotherapy ,Image-Guided ,Radiotherapy ,Intensity-Modulated ,Treatment Outcome ,Uterine Cervical Neoplasms ,Young Adult ,Gemcitabine ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeThe use of concurrent doublet chemotherapy with radiation for locoregionally advanced cervical cancer (LACC) is limited by gastrointestinal and hematologic toxicity. By reducing radiation dose to bowel and bone marrow, image guided intensity modulated radiation therapy (IG-IMRT) may improve chemotherapy tolerance. The goal of this study was to determine whether IG-IMRT could lead to improved tolerance to concurrent cisplatin and gemcitabine for LACC.Methods and materialsWe conducted an open-label, nonrandomized, prospective phase 1 dose escalation trial at a tertiary academic cancer center (ClinicalTrials.gov identifier: NCT01554410). We enrolled patients with stage IB-IVA cervical cancer, with either an intact cervix or posthysterectomy with residual/recurrent pelvic or paraortic nodal involvement, undergoing radical pelvic or extended field chemoradiation therapy. Treatment consisted of chemoradiation with IG-IMRT (45-47.6 Gy, 25-28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2-59.4 Gy, 28 fractions) plus 5 cycles of concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2). Cohorts were separated preregistration according to whether the patient received pelvic or extended field IG-IMRT and whether gemcitabine followed (CG) or preceded (GC) cisplatin delivery. Dose-limiting toxicity (DLT) events were monitored up to 30 days after chemoradiation therapy. The primary endpoint was maximum tolerated dose (MTD) resulting in DLT probability ≤20%.ResultsBetween February 2011 and June 2019, 35 patients were registered. Overall, 7 patients (20.0%) experienced DLTs. For the pelvic field cohort, the estimated MTD was 100 mg/m2 with GC sequencing, which is higher than the previously reported MTD for this regimen. The extended field cohort was closed after 2 of 3 patients experienced a DLT at the first dose level.ConclusionsIG-IMRT can permit higher doses of concurrent gemcitabine with cisplatin and pelvic radiation for LACC. However, acute toxicity remains a factor with this regimen, depending on radiation volume and chemotherapy sequencing.
- Published
- 2020
13. Contemporary image-guided cervical cancer brachytherapy: Consensus imaging recommendations from the Society of Abdominal Radiology and the American Brachytherapy Society
- Author
-
Jacobsen, Megan C., Beriwal, Sushil, Dyer, Brandon A., Klopp, Ann H., Lee, Susanna I., McGinnis, Gwendolyn J., Robbins, Jessica B., Rauch, Gaiane M., Sadowski, Elizabeth A., Simiele, Samantha J., Stafford, R. Jason, Taunk, Neil K., Yashar, Catheryn M., and Venkatesan, Aradhana M.
- Published
- 2022
- Full Text
- View/download PDF
14. The ABR 2021 Radiation Oncology Remote Examinations: Development, Administration, and Implications for the Future
- Author
-
Wallner, Paul E., Gerdeman, Anthony M., Warg, Lydia, Fussell, Meckenzie B., Segal, Scott, Gudenkauf, Kristin, Laszakovits, David, Bunting, Mathew, Davis, Brian J., Ng, Andrea K., Suh, John H., Yashar, Catheryn M., Alektiar, Kaled M., and Wagner, Brent J.
- Published
- 2022
- Full Text
- View/download PDF
15. Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy Reimbursement
- Author
-
Thaker, Nikhil G., Meghani, Rehman, Wilson, Cassandra, Garey, Jody, Nelson, Philip, Thaker, Gautam H., Shah, Chirag, Orio, Peter, Yashar, Catheryn M., and Kavadi, Vivek
- Published
- 2022
- Full Text
- View/download PDF
16. Neural network dose prediction for cervical brachytherapy: Overcoming data scarcity for applicator‐specific models.
- Author
-
Moore, Lance C., Ahern, Fritz, Li, Lingyi, Kallis, Karoline, Kisling, Kelly, Cortes, Katherina G., Nwachukwu, Chika, Rash, Dominique, Yashar, Catheryn M., Mayadev, Jyoti, Zou, Jingjing, Vasconcelos, Nuno, and Meyers, Sandra M.
- Subjects
RADIOISOTOPE brachytherapy ,DEEP learning ,SCARCITY ,ERROR functions ,CERVICAL cancer ,FORECASTING - Abstract
Background: 3D neural network dose predictions are useful for automating brachytherapy (BT) treatment planning for cervical cancer. Cervical BT can be delivered with numerous applicators, which necessitates developing models that generalize to multiple applicator types. The variability and scarcity of data for any given applicator type poses challenges for deep learning. Purpose: The goal of this work was to compare three methods of neural network training—a single model trained on all applicator data, fine‐tuning the combined model to each applicator, and individual (IDV) applicator models—to determine the optimal method for dose prediction. Methods: Models were produced for four applicator types—tandem‐and‐ovoid (T&O), T&O with 1–7 needles (T&ON), tandem‐and‐ring (T&R) and T&R with 1–4 needles (T&RN). First, the combined model was trained on 859 treatment plans from 266 cervical cancer patients treated from 2010 onwards. The train/validation/test split was 70%/16%/14%, with approximately 49%/10%/19%/22% T&O/T&ON/T&R/T&RN in each dataset. Inputs included four channels for anatomical masks (high‐risk clinical target volume [HRCTV], bladder, rectum, and sigmoid), a mask indicating dwell position locations, and applicator channels for each applicator component. Applicator channels were created by mapping the 3D dose for a single dwell position to each dwell position and summing over each applicator component with uniform dwell time weighting. A 3D Cascade U‐Net, which consists of two U‐Nets in sequence, and mean squared error loss function were used. The combined model was then fine‐tuned to produce four applicator‐specific models by freezing the first U‐Net and encoding layers of the second and resuming training on applicator‐specific data. Finally, four IDV models were trained using only data from each applicator type. Performance of these three model types was compared using the following metrics for the test set: mean error (ME, representing model bias) and mean absolute error (MAE) over all dose voxels and ME of clinical metrics (HRCTV D90% and D2cc of bladder, rectum, and sigmoid), averaged over all patients. A positive ME indicates the clinical dose was higher than predicted. 3D global gamma analysis with the prescription dose as reference value was performed. Dice similarity coefficients (DSC) were computed for each isodose volume. Results: Fine‐tuned and combined models showed better performance than IDV applicator training. Fine‐tuning resulted in modest improvements in about half the metrics, compared to the combined model, while the remainder were mostly unchanged. Fine‐tuned MAE = 3.98%/2.69%/5.36%/3.80% for T&O/T&R/T&ON/T&RN, and ME over all voxels = –0.08%/–0.89%/–0.59%/1.42%. ME D2cc were bladder = –0.77%/1.00%/–0.66%/–1.53%, rectum = 1.11%/–0.22%/–0.29%/–3.37%, sigmoid = –0.47%/–0.06%/–2.37%/–1.40%, and ME D90 = 2.6%/–4.4%/4.8%/0.0%. Gamma pass rates (3%/3 mm) were 86%/91%/83%/89%. Mean DSCs were 0.92%/0.92%/0.88%/0.91% for isodoses ≤ 150% of prescription. Conclusions: 3D BT dose was accurately predicted for all applicator types, as indicated by the low MAE and MEs, high gamma scores and high DSCs. Training on all treatment data overcomes challenges with data scarcity in each applicator type, resulting in superior performance than can be achieved by training on IDV applicators alone. This could presumably be explained by the fact that the larger, more diverse dataset allows the neural network to learn underlying trends and characteristics in dose that are common to all treatment applicators. Accurate, applicator‐specific dose predictions could enable automated, knowledge‐based planning for any cervical brachytherapy treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Erratum to: Fields EC, Erickson B, Hubbard A, Chino J, Small C, Weiner A, Petereit D, Mayadev JS, Yashar CM, Joyner M. Tipping the Balance: Adding Resources for Cervical Cancer Brachytherapy. Int J Radiat Oncol Biol Phys 2023;117:1138–1142
- Author
-
Fields, Emma C., primary, Erickson, Beth, additional, Hubbard, Anne, additional, Chino, Junzo, additional, Small, Christina, additional, Weiner, Ashley, additional, Petereit, Daniel, additional, Mayadev, Jyoti S., additional, Yashar, Catheryn M., additional, and Joyner, Melissa, additional
- Published
- 2024
- Full Text
- View/download PDF
18. ACR–ABS–ACNM–ASTRO–SIR–SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies
- Author
-
Hong, Kelvin, Akinwande, Olaguoke, Bodei, Lisa, Chamarthy, Murthy RK., Devlin, Phillip M., Elman, Shana, Ganguli, Suvranu, Kennedy, Andrew S., Koo, Sonya J., Ouhib, Zoubir, Padia, Siddharth A., Salem, Riad, Selwyn, Reed G., Yashar, Catheryn M., Yoo, Don C., Zaki, Bassem I., Hartford, Alan C., and Trimmer, Clayton K.
- Published
- 2021
- Full Text
- View/download PDF
19. NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update
- Author
-
Small, William, Jr., Bosch, Walter R., Harkenrider, Mathew M., Strauss, Jonathan B., Abu-Rustum, Nadeem, Albuquerque, Kevin V., Beriwal, Sushil, Creutzberg, Carien L., Eifel, Patricia J., Erickson, Beth A., Fyles, Anthony W., Hentz, Courtney L., Jhingran, Anuja, Klopp, Ann H., Kunos, Charles A., Mell, Loren K., Portelance, Lorraine, Powell, Melanie E., Viswanathan, Akila N., Yacoub, Joseph H., Yashar, Catheryn M., Winter, Kathryn A., and Gaffney, David K.
- Published
- 2021
- Full Text
- View/download PDF
20. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)
- Author
-
Mell, Loren K, Sirák, Igor, Wei, Lichun, Tarnawski, Rafal, Mahantshetty, Umesh, Yashar, Catheryn M, McHale, Michael T, Xu, Ronghui, Honerkamp-Smith, Gordon, Carmona, Ruben, Wright, Mary, Williamson, Casey W, Kasaová, Linda, Li, Nan, Kry, Stephen, Michalski, Jeff, Bosch, Walter, Straube, William, Schwarz, Julie, Lowenstein, Jessica, Jiang, Steve B, Saenz, Cheryl C, Plaxe, Steve, Einck, John, Khorprasert, Chonlakiet, Koonings, Paul, Harrison, Terry, Shi, Mei, Mundt, AJ, and Group, INTERTECC Study
- Subjects
Cervical Cancer ,Cancer ,Clinical Research ,Comparative Effectiveness Research ,Clinical Trials and Supportive Activities ,Adenocarcinoma ,Antineoplastic Agents ,Bone Marrow ,Brachytherapy ,Carcinoma ,Squamous Cell ,Chemoradiotherapy ,Cisplatin ,Feasibility Studies ,Female ,Gastrointestinal Tract ,Humans ,Incidence ,Middle Aged ,Neutropenia ,Organ Sparing Treatments ,Radiation-Sensitizing Agents ,Radiotherapy Dosage ,Radiotherapy ,Image-Guided ,Radiotherapy ,Intensity-Modulated ,Uterine Cervical Neoplasms ,INTERTECC Study Group ,Other Physical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeTo test the hypothesis that intensity modulated radiation therapy (IMRT) reduces acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced cervical cancer.Methods and materialsWe enrolled patients with stage IB-IVA cervical carcinoma in a single-arm phase II trial involving 8 centers internationally. All patients received weekly cisplatin concurrently with once-daily IMRT, followed by intracavitary brachytherapy, as indicated. The primary endpoint was the occurrence of either acute grade ≥3 neutropenia or clinically significant GI toxicity within 30 days of completing chemoradiation therapy. A preplanned subgroup analysis tested the hypothesis that positron emission tomography-based image-guided IMRT (IG-IMRT) would lower the risk of acute neutropenia. We also longitudinally assessed patients' changes in quality of life.ResultsFrom October 2011 to April 2015, 83 patients met the eligibility criteria and initiated protocol therapy. The median follow-up was 26.0 months. The incidence of any primary event was 26.5% (95% confidence interval [CI] 18.2%-36.9%), significantly lower than the 40% incidence hypothesized a priori from historical data (P=.012). The incidence of grade ≥3 neutropenia and clinically significant GI toxicity was 19.3% (95% CI 12.2%-29.0%) and 12.0% (95% CI 6.7%-20.8%), respectively. Compared with patients treated without IG-IMRT (n=48), those treated with IG-IMRT (n=35) had a significantly lower incidence of grade ≥3 neutropenia (8.6% vs 27.1%; 2-sided χ2P=.035) and nonsignificantly lower incidence of grade ≥3 leukopenia (25.7% vs 41.7%; P=.13) and any grade ≥3 hematologic toxicity (31.4% vs 43.8%; P=.25).ConclusionsIMRT reduces acute hematologic and GI toxicity compared with standard treatment, with promising therapeutic outcomes. Positron emission tomography IG-IMRT reduces the incidence of acute neutropenia.
- Published
- 2017
21. Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy
- Author
-
Noticewala, Sonal S, Li, Nan, Williamson, Casey W, Hoh, Carl K, Shen, Hanjie, McHale, Michael T, Saenz, Cheryl C, Einck, John, Plaxe, Steven, Vaida, Florin, Yashar, Catheryn M, and Mell, Loren K
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Bone Marrow ,Bone Marrow Diseases ,Chemoradiotherapy ,Female ,Humans ,Longitudinal Studies ,Middle Aged ,Positron Emission Tomography Computed Tomography ,Radiation Injuries ,Treatment Outcome ,Uterine Cervical Neoplasms ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeTo quantify longitudinal changes in active bone marrow (ABM) distributions within unirradiated (extrapelvic) and irradiated (pelvic) bone marrow (BM) in cervical cancer patients treated with concurrent chemoradiation therapy (CRT).Methods and materialsWe sampled 39 cervical cancer patients treated with CRT, of whom 25 were treated with concurrent cisplatin (40 mg/m2) and 14 were treated with cisplatin (40 mg/m2) plus gemcitabine (50-125 mg/m2) (C/G). Patients underwent 18F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging at baseline and 1.5 to 6.0 months after treatment. ABM was defined as the subvolume of bone with standardized uptake value (SUV) above the mean SUV of the total bone. The primary aim was to measure the compensatory response, defined as the change in the log of the ratio of extrapelvic versus pelvic ABM percentage from baseline to after treatment. We also quantified the change in the proportion of ABM and mean SUV in pelvic and extrapelvic BM using a 2-sided paired t test.ResultsWe observed a significant increase in the overall extrapelvic compensatory response after CRT (0.381; 95% confidence interval [CI]: 0.312, 0.449) and separately in patients treated with cisplatin (0.429; 95% CI: 0.340, 0.517) and C/G (0.294; 95% CI: 0.186, 0.402). We observed a trend toward higher compensatory response in patients treated with cisplatin compared with C/G (P=.057). Pelvic ABM percentage was reduced after CRT both in patients receiving cisplatin (P
- Published
- 2017
22. Implementation of peer-review quality rounds for gynecologic brachytherapy in a high-volume academic center
- Author
-
Huynh-Le, Minh-Phuong, Simon, Aaron B., Hoopes, David J., Einck, John P., Yashar, Catheryn M., Scanderbeg, Daniel, Rash, Dominique, Brown, Derek, Mell, Loren K., Sanghvi, Parag R., Mundt, Arno J., Pawlicki, Todd, and Mayadev, Jyoti S.
- Published
- 2020
- Full Text
- View/download PDF
23. ACR Appropriateness Criteria® Clinically Suspected Adnexal Mass, No Acute Symptoms: 2023 Update.
- Author
-
Patel-Lippmann, Krupa K., Wasnik, Ashish P., Akin, Esma A., Andreotti, Rochelle F., Ascher, Susan M., Brook, Olga R., Eskander, Ramez N., Feldman, Myra K., Jones, Lisa P., Martino, Martin A., Patel, Maitray D., Patlas, Michael N., Revzin, Margarita A., VanBuren, Wendaline, Yashar, Catheryn M., and Kang, Stella K.
- Abstract
Asymptomatic adnexal masses are commonly encountered in daily radiology practice. Although the vast majority of these masses are benign, a small subset have a risk of malignancy, which require gynecologic oncology referral for best treatment outcomes. Ultrasound, using a combination of both transabdominal, transvaginal, and duplex Doppler technique can accurately characterize the majority of these lesions. MRI with and without contrast is a useful complementary modality that can help characterize indeterminate lesions and assess the risk of malignancy is those that are suspicious. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations
- Author
-
Elledge, Christen R., Beriwal, Sushil, Chargari, Cyrus, Chopra, Supriya, Erickson, Beth A., Gaffney, David K., Jhingran, Anuja, Klopp, Ann H., Small, William, Jr, Yashar, Catheryn M., and Viswanathan, Akila N.
- Published
- 2020
- Full Text
- View/download PDF
25. Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma
- Author
-
Elshaikh, Mohamed A., Modh, Ankit, Jhingran, Anuja, Biagioli, Matthew C., Coleman, Robert L., Gaffney, David K., Harkenrider, Matthew M., Heskett, Karen, Jolly, Shruti, Kidd, Elizabeth, Lee, Larissa J., Li, Linna, Portelance, Lorraine, Sherertz, Tracy, Venkatessan, Aradhana M., Wahl, Andrew O., Yashar, Catheryn M., and Small, William, Jr
- Published
- 2020
- Full Text
- View/download PDF
26. Modern Radiation Therapy and Cardiac Outcomes in Breast Cancer
- Author
-
Boero, Isabel J, Paravati, Anthony J, Triplett, Daniel P, Hwang, Lindsay, Matsuno, Rayna K, Gillespie, Erin F, Yashar, Catheryn M, Moiseenko, Vitali, Einck, John P, Mell, Loren K, Parikh, Sahil A, and Murphy, James D
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Heart Disease - Coronary Heart Disease ,Heart Disease ,Prevention ,Aging ,Breast Cancer ,Cardiovascular ,Cancer ,2.4 Surveillance and distribution ,Aetiology ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Arrhythmias ,Cardiac ,Confidence Intervals ,Female ,Heart ,Heart Diseases ,Humans ,Medicare ,Myocardial Ischemia ,Percutaneous Coronary Intervention ,SEER Program ,Unilateral Breast Neoplasms ,United States ,Other Physical Sciences ,Clinical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeAdjuvant radiation therapy, which has proven benefit against breast cancer, has historically been associated with an increased incidence of ischemic heart disease. Modern techniques have reduced this risk, but a detailed evaluation has not recently been conducted. The present study evaluated the effect of current radiation practices on ischemia-related cardiac events and procedures in a population-based study of older women with nonmetastatic breast cancer.Methods and materialsA total of 29,102 patients diagnosed from 2000 to 2009 were identified from the Surveillance, Epidemiology, and End Results-Medicare database. Medicare claims were used to identify the radiation therapy and cardiac outcomes. Competing risk models were used to assess the effect of radiation on these outcomes.ResultsPatients with left-sided breast cancer had a small increase in their risk of percutaneous coronary intervention (PCI) after radiation therapy-the 10-year cumulative incidence for these patients was 5.5% (95% confidence interval [CI] 4.9%-6.2%) and 4.5% (95% CI 4.0%-5.0%) for right-sided patients. This risk was limited to women with previous cardiac disease. For patients who underwent PCI, those with left-sided breast cancer had a significantly increased risk of cardiac mortality with a subdistribution hazard ratio of 2.02 (95% CI 1.23-3.34). No other outcome, including cardiac mortality for the entire cohort, showed a significant relationship with tumor laterality.ConclusionsFor women with a history of cardiac disease, those with left-sided breast cancer who underwent radiation therapy had increased rates of PCI and a survival decrement if treated with PCI. The results of the present study could help cardiologists and radiation oncologists better stratify patients who need more aggressive cardioprotective techniques.
- Published
- 2016
27. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
- Author
-
Abu-Rustum, Nadeem R., primary, Yashar, Catheryn M., additional, Arend, Rebecca, additional, Barber, Emma, additional, Bradley, Kristin, additional, Brooks, Rebecca, additional, Campos, Susana M., additional, Chino, Junzo, additional, Chon, Hye Sook, additional, Crispens, Marta Ann, additional, Damast, Shari, additional, Fisher, Christine M., additional, Frederick, Peter, additional, Gaffney, David K., additional, Gaillard, Stephanie, additional, Giuntoli, Robert, additional, Glaser, Scott, additional, Holmes, Jordan, additional, Howitt, Brooke E., additional, Lea, Jayanthi, additional, Mantia-Smaldone, Gina, additional, Mariani, Andrea, additional, Mutch, David, additional, Nagel, Christa, additional, Nekhlyudov, Larissa, additional, Podoll, Mirna, additional, Rodabaugh, Kerry, additional, Salani, Ritu, additional, Schorge, John, additional, Siedel, Jean, additional, Sisodia, Rachel, additional, Soliman, Pamela, additional, Ueda, Stefanie, additional, Urban, Renata, additional, Wyse, Emily, additional, McMillian, Nicole R., additional, Aggarwal, Shaili, additional, and Espinosa, Sara, additional
- Published
- 2023
- Full Text
- View/download PDF
28. Phase II Trial of Five-Fraction Accelerated Partial Breast Irradiation (APBI) Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
- Author
-
Hepel, Jaroslaw T., primary, Leonard, Kara L., additional, Yashar, Catheryn M., additional, Einck, John P., additional, Sha, Sandra J., additional, DiPetrillo, Thomas A., additional, Wiggins, Doreen L., additional, Graves, Theresa A., additional, Edmonson, David A., additional, Gass, Jennifer S., additional, Rivard, Mark J., additional, Group, Brown University Oncology Research, additional, and Wazer, David E., additional
- Published
- 2023
- Full Text
- View/download PDF
29. An evaluation of gender diversity in the American Brachytherapy Society
- Author
-
Lu, Diana J., Luu, Michael, Yashar, Catheryn M., Klopp, Ann H., and Kamrava, Mitchell
- Published
- 2019
- Full Text
- View/download PDF
30. Clinical Outcomes of Computed Tomography–Based Volumetric Brachytherapy Planning for Cervical Cancer
- Author
-
Simpson, Daniel R, Scanderbeg, Daniel J, Carmona, Ruben, McMurtrie, Riley M, Einck, John, Mell, Loren K, McHale, Michael T, Saenz, Cheryl C, Plaxe, Steven C, Harrison, Terry, Mundt, Arno J, and Yashar, Catheryn M
- Subjects
Medical and Biological Physics ,Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Physical Sciences ,Reproductive Medicine ,Cervical Cancer ,Prevention ,Rare Diseases ,Biomedical Imaging ,Clinical Research ,Clinical Trials and Supportive Activities ,Cancer ,Adult ,Aged ,Aged ,80 and over ,Brachytherapy ,Female ,Humans ,Magnetic Resonance Imaging ,Interventional ,Middle Aged ,Radiotherapy Dosage ,Radiotherapy Planning ,Computer-Assisted ,Radiotherapy ,Image-Guided ,Tomography ,X-Ray Computed ,Uterine Cervical Neoplasms ,Young Adult ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
Purpose/objectivesA report of clinical outcomes of a computed tomography (CT)-based image guided brachytherapy (IGBT) technique for treatment of cervical cancer.Methods and materialsSeventy-six women with International Federation of Gynecology and Obstetrics stage IB to IVA cervical carcinoma diagnosed between 2007 and 2014 were treated with definitive external beam radiation therapy (EBRT) with or without concurrent chemotherapy followed by high-dose-rate (HDR) IGBT. All patients underwent planning CT simulation at each implantation. A high-risk clinical target volume (HRCTV) encompassing any visible tumor and the entire cervix was contoured on the simulation CT. When available, magnetic resonance imaging (MRI) was performed at implantation to assist with tumor delineation. The prescription dose was prescribed to the HRCTV.ResultsThe median follow-up time was 17 months. Thirteen patients (17%) had an MRI done before brachytherapy, and 16 patients (21%) were treated without MRI guidance. The mean EBRT/IGBT sum 2-Gy equivalent dose (EQD2) delivered to the 90% volume of the HRCTV was 86.3 Gy. The mean maximum EQD2s delivered to 2 cm(3) of the rectum, sigmoid, and bladder were 67.5 Gy, 66.2 Gy, and 75.3 Gy, respectively. The 2-year cumulative incidences of local, locoregional, and distant failure were 5.8% (95% confidence interval [CI]: 1.4%-14.8%), 15.1% (95% CI: 5.4%-29.4%), and 24.3% (95% CI: 12.1%-38.9%), respectively. The 2-year overall and disease-free survival rates were 75% (95% CI, 61%-91%) and 73% (95% CI, 60%-90%), respectively. Twenty-nine patients (38%) experienced grade ≥ 2 acute toxicity, with 5 cases of acute grade 3 toxicity and no grade ≥ 4 toxicities. One patient experienced grade 3 gastrointestinal toxicity. No other late grade ≥ 3 events were observed.ConclusionsThis is the largest report to date of CT/MRI-based IGBT for the treatment of cervical cancer. The results are promising, with excellent local control and acceptable toxicity. Further investigation is needed to assess the long-term safety and efficacy of this treatment.
- Published
- 2015
31. Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy
- Author
-
Zhu, He, Zakeri, Kaveh, Vaida, Florin, Carmona, Ruben, Dadachanji, Kaivan K, Bair, Ryan, Aydogan, Bulent, Hasan, Yasmin, Yashar, Catheryn M, and Mell, Loren K
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Radiation Oncology ,Infectious Diseases ,Hematology ,Cervical Cancer ,Sexually Transmitted Infections ,Women's Health ,Cancer ,Acute Disease ,Chemoradiotherapy ,Comorbidity ,Female ,Hematologic Diseases ,Humans ,Incidence ,Longitudinal Studies ,Male ,Middle Aged ,Radiation Injuries ,Radiotherapy Dosage ,Retrospective Studies ,Risk Factors ,Treatment Outcome ,United States ,Uterine Cervical Neoplasms ,acute hematologic function ,cervical cancer ,chemoradiotherapy ,longitudinal analysis ,Nursing ,Nuclear Medicine & Medical Imaging ,Clinical sciences ,Oncology and carcinogenesis - Abstract
IntroductionAcute hematologic toxicity (HT) limits optimal delivery of concurrent chemoradiotherapy (CRT) for patients with pelvic malignancies. We tested the hypothesis that pelvic bone marrow (PBM) dose-volume metrics were associated with weekly reductions in peripheral blood cell counts in cervical cancer patients undergoing CRT.MethodsWe included 102 cervical cancer patients treated with concurrent cisplatin (40 mg/m(2) /week) and pelvic radiotherapy treated at three US centres. No patient received granulocyte-monocyte colony stimulating factor (GM-CSF) or platelet transfusions. Using linear-mixed effects modelling, we analysed weekly reductions in log-transformed peripheral blood cell counts as a function of time (weeks), mean PBM dose and the PBM volume receiving ≥10 Gy (V(10)), 20 Gy (V(20)), 30 Gy (V(30)) and 40 Gy (V(40)).ResultsIncreases in mean PBM radiation dose, V(20), V(30) and V(40) were all significantly associated with a greater weekly reduction in white blood cell (WBC) and absolute neutrophil counts (ANCs). We estimated that with every 1 Gy increase in mean PBM dose, ln(ANC) was reduced by 9.6/μL per week (95% confidence interval, 1.9-17.3, P = 0.015). Subregion analysis also identified significant associations between weekly reductions in ln(WBC) and ln(ANC) within lumbosacral spine, ischium and proximal femora, as opposed to ilium.ConclusionsPBM radiation dose-volume metrics are significantly associated with weekly reductions in peripheral blood cell counts in cervical cancer patients undergoing CRT, particularly within the lower pelvis and lumbosacral spine.
- Published
- 2015
32. A segmentation and point-matching enhanced efficient deformable image registration method for dose accumulation between HDR CT images
- Author
-
Zhen, Xin, Chen, Haibin, Yan, Hao, Zhou, Linghong, Mell, Loren K, Yashar, Catheryn M, Jiang, Steve, Jia, Xun, Gu, Xuejun, and Cervino, Laura
- Subjects
Medical and Biological Physics ,Physical Sciences ,Cancer ,Algorithms ,Brachytherapy ,Female ,Genital Neoplasms ,Female ,Humans ,Image Processing ,Computer-Assisted ,Models ,Statistical ,Neoplasms ,Oropharyngeal Neoplasms ,Radiographic Image Interpretation ,Computer-Assisted ,Radiotherapy Planning ,Computer-Assisted ,Reproducibility of Results ,Tomography ,X-Ray Computed ,deformable registration ,brachytherapy ,gynecological cancer ,medical physics ,Other Physical Sciences ,Biomedical Engineering ,Clinical Sciences ,Nuclear Medicine & Medical Imaging ,Medical and biological physics - Abstract
Deformable image registration (DIR) of fractional high-dose-rate (HDR) CT images is challenging due to the presence of applicators in the brachytherapy image. Point-to-point correspondence fails because of the undesired deformation vector fields (DVF) propagated from the applicator region (AR) to the surrounding tissues, which can potentially introduce significant DIR errors in dose mapping. This paper proposes a novel segmentation and point-matching enhanced efficient DIR (named SPEED) scheme to facilitate dose accumulation among HDR treatment fractions. In SPEED, a semi-automatic seed point generation approach is developed to obtain the incremented fore/background point sets to feed the random walks algorithm, which is used to segment and remove the AR, leaving empty AR cavities in the HDR CT images. A feature-based 'thin-plate-spline robust point matching' algorithm is then employed for AR cavity surface points matching. With the resulting mapping, a DVF defining on each voxel is estimated by B-spline approximation, which serves as the initial DVF for the subsequent Demons-based DIR between the AR-free HDR CT images. The calculated DVF via Demons combined with the initial one serve as the final DVF to map doses between HDR fractions. The segmentation and registration accuracy are quantitatively assessed by nine clinical HDR cases from three gynecological cancer patients. The quantitative analysis and visual inspection of the DIR results indicate that SPEED can suppress the impact of applicator on DIR, and accurately register HDR CT images as well as deform and add interfractional HDR doses.
- Published
- 2015
33. Phase II Trial of Five-Fraction Accelerated Partial Breast Irradiation Using Noninvasive Image-Guided Breast Brachytherapy
- Author
-
Hepel, Jaroslaw T., Leonard, Kara L., Yashar, Catheryn M., Einck, John P., Sha, Sandra J., DiPetrillo, Thomas A., Wiggins, Doreen L., Graves, Theresa A., Edmonson, David A., Gass, Jennifer S., Rivard, Mark J., and Wazer, David E.
- Published
- 2024
- Full Text
- View/download PDF
34. Impact of marital status on receipt of brachytherapy and survival outcomes in locally advanced cervical cancer
- Author
-
Huynh-Le, Minh-Phuong, Klapheke, Amy, Cress, Rosemary, Mell, Loren K., Yashar, Catheryn M., Einck, John P., Mundt, Arno J., and Mayadev, Jyoti S.
- Published
- 2019
- Full Text
- View/download PDF
35. Understanding the underutilization of cervical brachytherapy for locally advanced cervical cancer
- Author
-
Ma, Ting Martin, Harkenrider, Matthew M., Yashar, Catheryn M., Viswanathan, Akila N., and Mayadev, Jyoti S.
- Published
- 2019
- Full Text
- View/download PDF
36. Brachytherapy Training Survey of Radiation Oncology Residents
- Author
-
Marcrom, Samuel R., Kahn, Jenna M., Colbert, Lauren E., Freese, Christopher M., Doke, Kaleigh N., Yang, Joanna C., Yashar, Catheryn M., Luu, Michael, and Kamrava, Mitchell
- Published
- 2019
- Full Text
- View/download PDF
37. The impact of daily bladder filling on small bowel dose for intensity modulated radiation therapy for cervical cancer
- Author
-
Chen, Victor E., Gillespie, Erin F., Manger, Ryan P., Skerritt, Lauren A., Tran, Josephine H., Proudfoot, James A., Sherer, Michael V., Einck, John P., Mell, Loren K., Moore, Kevin L., and Yashar, Catheryn M.
- Published
- 2019
- Full Text
- View/download PDF
38. Validated Competing Event Model for the Stage I-II Endometrial Cancer Population
- Author
-
Carmona, Ruben, Gulaya, Sachin, Murphy, James D, Rose, Brent S, Wu, John, Noticewala, Sonal, McHale, Michael T, Yashar, Catheryn M, Vaida, Florin, and Mell, Loren K
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Prevention ,Clinical Research ,Cancer ,Good Health and Well Being ,Adenocarcinoma ,Age Factors ,Aged ,Cause of Death ,Chi-Square Distribution ,Comorbidity ,Endometrial Neoplasms ,Female ,Humans ,Hysterectomy ,Medicare ,Middle Aged ,Models ,Statistical ,Neoplasm Staging ,Regression Analysis ,Risk ,SEER Program ,Socioeconomic Factors ,Survival Analysis ,United States ,Other Physical Sciences ,Clinical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
Purpose/objectives(s)Early-stage endometrial cancer patients are at higher risk of noncancer mortality than of cancer mortality. Competing event models incorporating comorbidity could help identify women most likely to benefit from treatment intensification.Methods and materials67,397 women with stage I-II endometrioid adenocarcinoma after total hysterectomy diagnosed from 1988 to 2009 were identified in Surveillance, Epidemiology, and End Results (SEER) and linked SEER-Medicare databases. Using demographic and clinical information, including comorbidity, we sought to develop and validate a risk score to predict the incidence of competing mortality.ResultsIn the validation cohort, increasing competing mortality risk score was associated with increased risk of noncancer mortality (subdistribution hazard ratio [SDHR], 1.92; 95% confidence interval [CI], 1.60-2.30) and decreased risk of endometrial cancer mortality (SDHR, 0.61; 95% CI, 0.55-0.78). Controlling for other variables, Charlson Comorbidity Index (CCI) = 1 (SDHR, 1.62; 95% CI, 1.45-1.82) and CCI >1 (SDHR, 3.31; 95% CI, 2.74-4.01) were associated with increased risk of noncancer mortality. The 10-year cumulative incidences of competing mortality within low-, medium-, and high-risk strata were 27.3% (95% CI, 25.2%-29.4%), 34.6% (95% CI, 32.5%-36.7%), and 50.3% (95% CI, 48.2%-52.6%), respectively. With increasing competing mortality risk score, we observed a significant decline in omega (ω), indicating a diminishing likelihood of benefit from treatment intensification.ConclusionComorbidity and other factors influence the risk of competing mortality among patients with early-stage endometrial cancer. Competing event models could improve our ability to identify patients likely to benefit from treatment intensification.
- Published
- 2014
39. Uterine Cancer
- Author
-
Paravati, Anthony J, Simpson, Daniel R, Yashar, Catheryn M, Mell, Loren K, and Mundt, Arno J
- Subjects
Cancer - Published
- 2014
40. Cervical Cancer
- Author
-
Simpson, Daniel R., Paravati, Anthony J., Yashar, Catheryn M., Mell, Loren K., Mundt, Arno J., Brady, Luther W., Series Editor, Combs, Stephanie E., Series Editor, Lu, Jiade J., Series Editor, Heilmann, Hans-Peter, Series Editor, Molls, Michael, Series Editor, Lee, Nancy Y., editor, and Riaz, Nadeem, editor
- Published
- 2015
- Full Text
- View/download PDF
41. Uterine Cancer
- Author
-
Paravati, Anthony J., Simpson, Daniel R., Yashar, Catheryn M., Mell, Loren K., Mundt, Arno J., Brady, Luther W., Series Editor, Combs, Stephanie E., Series Editor, Lu, Jiade J., Series Editor, Heilmann, Hans-Peter, Series Editor, Molls, Michael, Series Editor, Lee, Nancy Y., editor, and Riaz, Nadeem, editor
- Published
- 2015
- Full Text
- View/download PDF
42. Gynecologic Malignancies
- Author
-
Simpson, Daniel R., Paravati, Anthony J., Yashar, Catheryn M., Mell, Loren K., Mundt, Arno J., Nishimura, Yasumasa, editor, and Komaki, Ritsuko, editor
- Published
- 2015
- Full Text
- View/download PDF
43. Radiation Therapy in Gynecologic Cancer
- Author
-
McDuff, Susan G. R., Yashar, Catheryn M., Eskander, Ramez N., editor, and Bristow, Robert E., editor
- Published
- 2015
- Full Text
- View/download PDF
44. Assessment of contouring resource use and awareness of contouring guidelines among radiation oncologists
- Author
-
Sherer, Michael V., Bryant, Alex K., Wu, Abraham J., Barry, Parul N., Lally, Brian E., Yashar, Catheryn M., Murphy, James D., and Gillespie, Erin F.
- Published
- 2018
- Full Text
- View/download PDF
45. Basic Principles in Gynecologic Radiotherapy
- Author
-
Yashar, Catheryn M., primary
- Published
- 2018
- Full Text
- View/download PDF
46. Contributors
- Author
-
Babb, Sheri A., primary, Backes, Floor J., additional, Barber, Emma L., additional, Brewster, Wendy R., additional, Chase, Dana M., additional, Chu, Christina S., additional, Clarke-Pearson, Daniel L., additional, Cohn, David E., additional, Coleman, Robert L., additional, Copeland, Larry J., additional, Cronin, Patricia A., additional, Creasman, William T., additional, Di Saia, Philip J., additional, Doll, Kemi M., additional, Eisenhauer, Eric L., additional, Fowler, Jeffrey M., additional, Gemignani, Mary L., additional, Gunderson, Camille C., additional, Hamilton, Chad A., additional, Herzog, Thomas J., additional, Hope, Erica R., additional, Huang, Marilyn, additional, Landrum, Lisa M., additional, Mannel, Robert S., additional, Marcus, Charlotte S., additional, Massad, L. Stewart, additional, Mathews, Cara A., additional, Maxwell, G. Larry, additional, McMeekin, D. Scott, additional, Miller, David Scott, additional, Monk, Bradley J., additional, Mutch, David G., additional, Penick, Emily R., additional, Rubin, Stephen C., additional, Salani, Ritu, additional, Slomovitz, Brian M., additional, Sood, Anil K., additional, Soper, John T., additional, Tewari, Krishnansu S., additional, Walker, Joan L., additional, Wenzel, Lari B., additional, Westin, Shannon N., additional, Wong, Siu-Fun, additional, Yashar, Catheryn M., additional, and Zuna, Rosemary E., additional
- Published
- 2018
- Full Text
- View/download PDF
47. Saturday, June 18, 20229:30 AM - 10:30 AM GPP06 Presentation Time: 9:30 AM
- Author
-
Jacobsen, Megan, primary, Beriwal, Sushil, additional, Dyer, Brandon A., additional, Klopp, Ann H., additional, Lee, Susanna I., additional, McGinnis, Gwendolyn J., additional, Robbins, Jessica B., additional, Rauch, Gaiane M., additional, Sadowski, Elizabeth A., additional, Simiele, Samantha J., additional, Taunk, Neil K., additional, Yashar, Catheryn M., additional, and Venkatesan, Aradhana M., additional
- Published
- 2022
- Full Text
- View/download PDF
48. 22 - Basic principles in gynecologic radiotherapy
- Author
-
Rash, Dominique Lan and Yashar, Catheryn M.
- Published
- 2023
- Full Text
- View/download PDF
49. Comparison and Consensus Guidelines for Delineation of Clinical Target Volume for CT- and MR-Based Brachytherapy in Locally Advanced Cervical Cancer
- Author
-
Viswanathan, Akila N., Erickson, Beth, Gaffney, David K., Beriwal, Sushil, Bhatia, Sudershan K., Lee Burnett, Omer, III, D'Souza, David P., Patil, Nikhilesh, Haddock, Michael G., Jhingran, Anuja, Jones, Ellen L., Kunos, Charles A., Lee, Larissa J., Lin, Lilie L., Mayr, Nina A., Petersen, Ivy, Petric, Primoz, Portelance, Lorraine, Small, William, Jr., Strauss, Jonathan B., Townamchai, Kanokpis, Wolfson, Aaron H., Yashar, Catheryn M., and Bosch, Walter
- Published
- 2014
- Full Text
- View/download PDF
50. Implementation of a High-Dose-Rate Brachytherapy Program for Carcinoma of the Cervix in Senegal: A Pragmatic Model for the Developing World
- Author
-
Einck, John P., Hudson, Alana, Shulman, Adam C., Yashar, Catheryn M., Dieng, Mamadou M., Diagne, Magatte, Gueye, Latifatou, Gningue, Fama, Gaye, Pape M., Fisher, Brandon J., Mundt, Arno J., and Brown, Derek W.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.